Nano vaccine taking SARS-CoV-2 virus S protein RBD region as antigen and preparation method of nano vaccine

A nano-vaccine, sars-cov-2 technology, which is applied in the preparation of the nano-self-assembled particle protein vaccine and the field of nano-self-assembled particle protein vaccine, and achieves the effects of high safety, good antigenicity and facilitating process expansion.

Inactive Publication Date: 2020-12-04
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although nano-self-assembled particle vaccine technology is expected to provide a new breakthrou

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nano vaccine taking SARS-CoV-2 virus S protein RBD region as antigen and preparation method of nano vaccine
  • Nano vaccine taking SARS-CoV-2 virus S protein RBD region as antigen and preparation method of nano vaccine
  • Nano vaccine taking SARS-CoV-2 virus S protein RBD region as antigen and preparation method of nano vaccine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: Preparation of the nanometer self-assembled particle protein vaccine of the present invention.

[0033] Cell transfection plasmid preparation

[0034] 1) The gene sequence of the SARS-CoV-2 virus S protein RBD region (as shown in the sequence table SEQ ID NO.2) is optimized according to the codons of the human expression system and the whole gene is synthesized, and constructed on the pc3.1+ vector backbone .

[0035] 2) Construction of the plasmid The correct expression frame was verified by sequencing, and the E. coli seed bank of the target plasmid was established.

[0036] 3) Use the endotoxin removal plasmid kit to extract the SARS-CoV-2 virus S protein RBD region expression plasmid.

[0037] Protein expression conditions in different cell lines

[0038] 1. Protein expression in 293T cell system

[0039] The SARS-CoV-2 virus S protein RBD region expression plasmid was transiently transfected into 293T cells:

[0040] 1) Use a 10cm culture plate for ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a nano vaccine taking an SARS-CoV-2 virus S protein RBD region as an antigen and a preparation method of the nano vaccine. An expression vector with an SARS-CoV-2 virus S protein RBD region gene sequence is transfected into 293T, 293i and CHO cell lines for antibody expression, and the required vaccine is obtained after protein extraction, ultrafiltration enrichment, antibody affinity chromatography purification, protein collection after purification, PBS dialysis and aluminum hydroxide adjuvant mixed incubation. The vaccine is a protein for expressing an amino acid sequence of the SARS-CoV-2 virus S protein RBD region, 24 monomers in a cell can be self-assembled into a sphere structure, and an SARS-CoV-2 virus S protein RBD peptide fragment subjected to fusion expression is displayed on the surface of a sphere. The vaccine has high neutralizing activity on the SARS-CoV-2 virus, and can effectively inhibit infection of the virus on vero cells. A toxicity attacking experiment shows that the vaccine can obviously and effectively protect the infection and damage of the SARS-CoV-2 to rhesus monkeys, and an excellent candidate vaccine is provided for the prevention and control of the current COVID-19 epidemic situation.

Description

technical field [0001] The invention belongs to the technical field of coronavirus vaccine preparation, in particular to a nanometer self-assembled granular protein vaccine with good neutralizing activity against SARS-CoV-2 virus. At the same time, the invention also relates to a preparation method of the nanometer self-assembled granular protein vaccine. Background technique [0002] In recent years, vaccine preparation technology has been continuously developed, and the newly emerged nano-self-assembled particle vaccine has the following advantages: fast preparation, simple purification process, easy to scale up, multiple antigen monomer polymerization display makes antigenicity higher, and is produced by human cell fermentation Higher security. For example, the technology of displaying the conserved antigenic sites of influenza virus on the surface of self-assembled nanoparticles to enhance vaccine antigenicity and safety has been widely used in the development of univer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/215A61P31/14C12N15/85C12N15/50
CPCA61K39/12A61P31/14C12N15/85C07K14/005C12N2800/107C12N2770/20022C12N2770/20034A61K2039/55505
Inventor 刘龙丁李恒郭磊郑惠文梁燕杨泽宁陈燕丽和占龙施海晶李菁
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap